Search PubMed⌕ Search

Biomedical subjects

G Visco

Publications and source records attributed to G Visco.

At least 37 records · Page 2Linked to original sources
PubMed1990

The efficacy and safety of imipenem/cilastatin in the treatment of severe bacterial infections.

We have assessed the efficacy and safety of imipenem/cilastatin in a non-comparative study of 27 immunocompromised patients suffering from severe bacterial infections. Moreover in two groups of 14 patients the efficacy of imipenem/cilastatin versus a standard broad spectrum antibiotic therapy has also been compared. Clinical and microbiological efficacy and side effects have been evaluated.

Adolescent↗
PubMed1990

Hepatitis C virus infection in intravenous drug users: prevalence and risk factors.

We investigated the relation of drug use and sexual behaviour to hepatitis C virus (HCV) infection among 80 intravenous drug users (IVDU) attending a methadone treatment program in Rome. Antibodies to HCV (anti-HCV) were found in 54/80 of IVDU (67.5%). Presence of anti-HCV was associated with duration of intravenous drug use and frequency of needle sharing (p less than 0.003 and p = 0.02, respectively, by chi-square for trend). No association was found between sexual behaviour and anti-HCV prevalence.

Adolescent↗
PubMed1989

[Piperacillin in the therapy of severe bacterial infections: comparison of its efficacy and tolerance vs. ceftazidime].

38 patients with severe acute bacterial systemic infections have been enrolled in this study: 19 patients were treated with piperacillin (100-200 mg/kg/day) and 19 with ceftazidime (45-90 mg/kg/day) by i.v. route. In both groups monotherapy has been found effective and well tolerated. Serious side-effects have not been observed. The high cure and eradication rates in both groups do not show statistically significant differences (chi 2 = 0.620 and chi 2 = 0.219, respectively, p greater than 0.05).

Adult↗
PubMed1989

[Cefotetan vs ceftriaxone: clinical and bacteriological efficacy in complicated forms of urinary tract infection].

Forty adult patients with UTI complicated by local and/or general diseases have been treated, 20 with Cefotetan and 20 with Ceftriaxone. Both treatments showed good clinical and bacteriological efficacy, with no statistically significant differences between the results. Cefotetan and Ceftriaxone were both well tolerated, without any local or systemic side effects.

Adolescent↗
PubMed1989

[Enoxacin in the treatment of bacterial infections of the urinary tract].

In order to evaluate effectiveness and tolerance of treatment with 300 mg tablets of enoxacine (one every 12 hours), 30 patients between the ages of 29 and 75 were selected (51.23 +/- 2.19 yrs. was the average age), 4 males and 26 females; 18 patients had acute cystitis, 7 had pyelonephritis, 4 had cystopyelitis, and 1 had urethroprostatitis. Treatment lasted on average of 10.77 +/- 0.52 days, with a minimum of 7 and a maximum of 20 days. Initial culture analysis of urine samples ascertained the presence of microbial pathogens sensitive to enoxacine. After one week of treatment, culture analysis of urine samples did not reveal the presence of these pathogens, all having been successfully eliminated. The improvement of the objective and symptomatic parameters chosen for evaluating the effectiveness of the treatment was found to be rapid and decisive in the majority of patients. The systemic tolerance was good; the side effects were minimal (three cases of slight gastroenteric intolerance). At the end of treatment, results were considered excellent in 18 patients and good in 12, on the basis of the more or less rapid resolution of the clinical and symptomatic situation.

Adult↗
PubMed1986

Treatment of chronic HBeAg-positive hepatitis with acyclovir. A controlled trial.

In a previous study a partial inhibition of viral replication was observed in HBeAg-positive patients after acyclovir (ACV) treatment. To assess those results and to evaluate different treatment regimens, a randomized controlled trial with ACV given at 45 mg/kg/day by continuous infusion (in 5 patients) or by intermittent 8-hourly infusion (in 6 patients) for 28 days versus placebo has been performed in 20 patients affected by chronic hepatitis positive for both HBsAg and HBeAg for at least 6 months. Patients were stratified for sex, presence of cirrhosis and homosexual activity. Modest inhibition of serum DNA polymerase activity was observed after intermittent ACV treatment but not with the continuous infusion. After a 8-12 months follow-up, 2 of 10 of the ACV-treated patients and 3 of the controls had become HBeAg-negative, with 1 and 2 seroconversions to anti-HBe in the treated and placebo group respectively. No adverse effects were observed in ACV-treated patients after continuous infusion, but 2 of 6 patients who received intermittent therapy had to stop treatment, because of abdominal colics and elevation of the serum creatinine. Our data confirm that ACV partially inhibits viral replication in HBeAg-positive patients but without significantly affecting the rate of seroconversion to anti-HBe.

Acyclovir↗
PubMed1986

An open study of human lymphoblastoid interferon and oral acyclovir in chronic hepatitis B virus infection.

Ten patients were entered into an open study of interferon (IFN) 'induction' and oral acyclovir (ACV) 'maintenance' therapy. They received 5 Mega units (Mu)/m2 IFN by intramuscular injection daily for 3 days, followed by 7.5 Mu/m2 IFN daily for 7 days. IFN therapy was then discontinued and a 6-week course of oral ACV at a dose of 800 mg 4 times daily commenced. At 6 months, 2 patients had become HBeAg-negative and 1 had developed anti-HBe. Elimination of HBeAg in these patients was accompanied by return of serum liver function tests to normal. There was a statistically significant inhibition of DNA polymerase levels after the 1st week of IFN therapy, which then slowly increased to pretreatment values over 8 weeks. There were no significant adverse effects of ACV therapy, while fever, 'flu-like illness', fatigue, anorexia, and leucopenia were the main side-effects observed during the course of IFN which necessitated dose reduction in 7 patients. Combination therapy appears to effectively inhibit viral replication, although the 'maintenance' effect of oral ACV is minimal. A more effective drug to combine with IFN is needed.

Acyclovir↗
PubMed1984

Modifying risk of developing lung cancer by changing habits of cigarette smoking.

Data from a hospital based case-control study of lung cancer in Western Europe were used to examine changes in the risk of developing lung cancer after changes in habits of cigarette smoking. Only data for subjects who had smoked regularly at some time in their lives were included. The large size of the study population (7181 patients and 11 006 controls) permitted precise estimates of the effect of giving up smoking. Risks of developing lung cancer for people who had given up smoking 10 or more years before interview were less than half of those for people who continued to smoke. The reduction in risk was seen in men and women and in former smokers of both filter and non-filter cigarettes but varied by duration of smoking habit before giving up. The protective effect of giving up became progressively greater with shorter duration of smoking habit. The risks after not smoking for 10 years for both men and women who had previously smoked for less than 20 years were roughly the same as those for lifelong non-smokers. Reducing the number of cigarettes smoked a day or switching from non-filter to filter cigarettes also lowered the risk of developing lung cancer but not to the extent associated with giving up smoking.

Europe↗
PubMed1984

Patterns of lung cancer risk according to type of cigarette smoked.

A case-control study of lung cancer involving interviews with 7,804 cases and 15,207 hospital-based controls was carried out in seven locations in Western Europe. The large study size permitted the calculation of precise estimates of the relative risk of lung cancer associated with smoking different types of cigarettes. Lifelong nonfilter smokers were at nearly twice the risk of lung cancer compared to lifelong filter smokers after controlling for duration of cigarette use and number smoked per day (RR = 1.7 for males and 2.0 for females). Lung cancer risks for filter, nonfilter and mixed smokers increased in proportion to intensity and duration of smoking and decreased with years since stopping smoking. The findings indicate that prevention activities should continue to emphasize smoking cessation, although switching to low-tar cigarettes may also yield some reductions in lung cancer risk.

Adult↗